First in Human, Dose Escalation, Dose Expansion Study of AUR105

Phase 1 Terminated 17 enrolled Aurigene Discovery Technologies Limited

NaSequentialOpen-labelTreatment

Summary

This is a multi-center, open-label, First in Human, Phase 1 study of AUR 105 in adult patients with advanced malignancies. The study will have two parts: a Dose Escalation Part and Dose Expansion Part.

Timeline

Start: 2022-11-30
Primary completion: 2024-03-01
Completion: 2024-03-01

Outcome

Outcome not reported

Stopped (Enrollment): “Patient recruitment problems.”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AUR105	Unknown	50 mg	Oral
Subject	AUR105	Unknown	100 mg	Oral
Subject	AUR105	Unknown	200 mg	Oral
Subject	AUR105	Unknown	300 mg	Oral
Subject	AUR105	Unknown	450 mg	Oral
Subject	AUR105	Unknown	600 mg	Oral
Subject	AUR105	Unknown	740 mg	Oral

First in Human, Dose Escalation, Dose Expansion Study of AUR105

Summary

Timeline

Outcome

Drugs

Indications